摘要
目的探讨噻托溴铵(思力华)联合沙美特罗替卡松(舒利迭)雾化吸入在慢阻肺是慢性阻塞性肺病(Chronic Obstructive Pulmonary Diseases,COPD)治疗中的效果,为今后的临床用药提供思路。方法选取2013年1月~2014年1月期间我院呼吸科门诊收治的100例COPD患者作为本组研究的观察对象,随机将其分为对照组与观察组各50例,两组患者均给予相同的对症治疗(解痉、平喘、祛痰、抗炎等),对照组在上述治疗的基础上采用沙美特罗替卡松雾化吸入,观察组在此基础上口服噻托溴铵,治疗6个月后对比两组患者的第1秒用力呼气容积(FEVl)、FEV占预计值百分比(FEVl%pred)以及用力肺活量(FVC),并比较住院次数与发作次数。结果(1)治疗后,观察组的FEVl、FEVl%pred以及FVC均优于对照组,具有统计学意义,P〈0.05。(2)观察组的住院时间、发作次数均明显低于对照组,有统计学意义,P〈0.05。结论噻托溴铵联合沙美特罗替卡松雾化吸入可以明显改善COPD患者的肺功能,降低发作次数,减少住院次数,提高患者的生活质量。
Objective To explore Sai supporting bromide combined salmeterol for Casson atomization inhalation in chronic obstructive pulmonary disease is the effect in the treatment of chronic obstructive pulmonary disease, provide ideas for future clinical application. Methods During the period of January 2013 to 2014 January in our hospital respiratory clinic treated 100 cases of COPD patients as the research object of observation were divided into control group and observation group, 50 cases in each group. Patients in the two groups were given the same symptomatic treatment and control group on the basis of the treatment with salmeterol and fluticasone propionate aerosol inhalation, the observation group on the basis of oral tiotropium bromide, 6 months after treatment were compared between the two groups of FEVl, FEVl, pred, FVC, and compared hospitalization times and episodes. Results(1) after treatment, the observation group FEVl, FVC and FEVl, pred were significantly better than the control group, with statistical significance, P〈0.05.(2) the hospitalization time and the number of attacks in the observation group were significantly lower than those in the control group, and the P〈0.05. Conclusion Tiotropium bromide combined salmeterol for Casson atomization inhalation can significantly improve lung function in patients with chronic obstructive pulmonary disease(COPD), reduce attack frequency, reduce the times of hospitalization, improve the quality of life of patients.
出处
《中国继续医学教育》
2015年第18期185-186,共2页
China Continuing Medical Education